February 27, 2019
ARLINGTON, Va. — Healthcare Distribution Alliance (HDA) President and CEO John M. Gray issued a statement in response to the Drug Enforcement Administration’s (DEA) announcement of an enhanced data tool to support additional information sharing with pharmaceutical distributors and manufacturers.
“The DEA has taken an important step to enhance data transparency and address a persistent information gap between the agency and its supply chain registrants. HDA and the nation’s primary pharmaceutical distributors have long advocated for increased information sharing through greater access to data from the Automation of Reports and Consolidated Orders System (ARCOS). Facilitated through the newly enacted SUPPORT for Patients and Communities Act, this resource will enable distributors and their supply chain partners to view a more complete picture of controlled substance sales.
“HDA and its distributor members look forward to continued collaboration with DEA and other stakeholders as the SUPPORT Act is implemented, and we continue to seek forward-looking solutions to end the nation’s prescription opioid abuse epidemic.”
For more information on pharmaceutical distribution industry efforts to combat the prescription opioid epidemic, visit the HDA website.
The Healthcare Distribution Alliance (HDA) represents primary pharmaceutical distributors — the vital link between the nation’s pharmaceutical manufacturers and pharmacies, hospitals, long-term care facilities, clinics and others nationwide. Since 1876, HDA has helped members navigate regulations and innovations to get the right medicines to the right patients at the right time, safely and efficiently. The HDA Research Foundation, HDA’s non-profit charitable foundation, serves the healthcare industry by providing research and education focused on priority healthcare supply chain issues.